

The Bulletin

This monthly bulletin includes recent changes to our medical policies and reimbursement policies. It is a supplement to our bimonthly provider newsletter, [*The Connection*](#). **Note:** Medication and dental policy updates are published in *The Connection*.

Medical policies

Commercial

Changes effective July 1, 2023

Durable Medical Equipment

- Negative Pressure Wound Therapy in the Outpatient Setting (#42)
 - Clarified policy criteria

Changes effective August 1, 2023

Surgery

- Implantable Cardioverter Defibrillator (#17)
 - Reformatted criteria for clarity
 - Added criteria specific to arrhythmogenic right ventricular cardiomyopathy (ARVC)

Changes effective November 1, 2023

Allied Health

- Enteral and Oral Nutrition Therapy in the Home Setting (#05)
 - New commercial medical policy applies only to Individual members

Genetic Testing

- Identification of Microorganisms Using Nucleic Acid Probes (#85)
 - Updating policy to consider respiratory pathogen panel testing with 12 or more targets to be investigational

Surgery

- Hysterectomy (#218)
 - New commercial medical policy applies only to Individual members and will include pre-authorization requirements for select diagnosis codes

Utilization Management

- Air Ambulance Transport (#13)
 - Updating commercial medical policy to add post-service review for Individual members

[View our commercial Medical Policy Manual](#)

Medicare Advantage

There were no recent Medicare Advantage medical policy updates.

[View our Medicare Advantage Medical Policy Manual](#)

Join our medical policy discussion

We welcome your input and feedback as we draft our medical policies. [Join our email reviewer list](#). While we prefer to receive input as policies are developed, we also have a formal process that allows you to submit additional information, such as clinical trial results, that may warrant a policy review.

Recent updates and archived medical policies

[Recent updates and archived medical policies](#) may include revisions that will be published in the next issue of *The Bulletin*.

Reimbursement policies

Commercial

Changes effective July 1, 2023

Medicine

- Cellular and Gene Therapy Products (#112)
 - Moved omidubicel to new section of revised appendix

Medicare Advantage

There were no recent Medicare Advantage reimbursement policy updates.

View our Reimbursement Policy Manual

Join our reimbursement policy discussion

Comments from physicians and other health care professionals regarding reimbursement policies are welcome. If you have a comment regarding a reimbursement policy, please complete the [Reimbursement Policy Feedback Form](#).

Verify your provider information

Providing up-to-date and accurate information about the providers in each of our networks is critical for our members to access care and a compliance requirement for the Affordable Care Act (ACA) and Medicare Advantage plans.

Validating provider directory content

Please [follow these steps](#) to review the information about your practice every 90 days. **Please respond timely to any requests from us for verification of your directory data.**

If your clinic or facility submits provider rosters to us, please submit changes, corrections, additions or terminations immediately so we can update our directories as soon as possible. **Your roster must be validated and reviewed in its entirety at least once per quarter.**

We appreciate your assistance in keeping information about your practice up to date.

[Subscribe](#) | [Unsubscribe](#) | [Update preferences](#) | [Online privacy and security](#)

© 2023 Asuris P.O. Box 91130 Seattle, WA, 98111-9230, USA